Physician profile
Weihan Wang
NPI 1982875449
$2,670.47
in general payments reported to CMS, 2019-2025
23 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $346 · 2021: $108 · 2022: $445 · 2023: $82.62 · 2024: $665 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,181.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $822.45 | 2019-2025 | Vemlidy, Livdelzi |
| Otsuka America Pharmaceutical, INC. | $257.99 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $245.68 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $206.35 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $195.45 | 2020-2022 | |
| Eisai INC. | $143.26 | 2021-2024 | |
| Amgen INC. | $137.52 | 2021-2025 | Evenity, Prolia |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Novo Nordisk INC | $99.21 | 2019-2022 | |
| Vertos Medical, INC. | $77.74 | 2019 | |
| Acadia Pharmaceuticals INC | $47.17 | 2019-2023 | Nuplazid |
| Exact Sciences Corporation | $40.24 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $38.46 | 2019 | |
| Biogen, INC. | $31.01 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.76 | 2025 | Caplyta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.74 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $26.98 | 2024 | |
| Avanir Pharmaceuticals, INC. | $24.09 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.45 | 2025 | Xifaxan |
| Collegium Pharmaceutical, INC. | $22.22 | 2024 | Xtampza |
| Lilly USA, LLC | $18.27 | 2025 | Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.31 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weihan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.